ARTL

Artelo Biosciences

ARTL

Attention (50-day avg)0%

Attention rank (50-day avg)#840

Bullish sentiment (50-day avg)83%

Price to earnings ratio-0.12

Market capitalization2.4M

Earnings per share-101.1

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-12.9M

Social

What share of all stock conversation is about ARTL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0.02% +0.02	0.01% +0	0% +0

Sep 24

The stock price of ARTL surged from around $4 to $7.31, breaking through the $5.46 area with significant momentum and volume.
The company's stock has experienced a significant increase, with some investors reporting gains of over 75% in a short period, despite previous volatility and haltings.
The stock's low float and high volatility have contributed to its potential for significant price movements, with some investors anticipating further increases in the stock's price.

Generated by AI

Sentiment

Of the messages about ARTL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% -50	83.08% -7.83	83.58% +1.76	78.83% -1.56
Bearish	50% new	16.92% +7.83	16.42% -1.76	21.17% +1.56

Bullish· Sep 23

The company has already shown significant price appreciation, rising by 168% from $4.70 to $12.63, and is expected to continue its upward trend with a potential daily expansion move to $14.60+.
The asset's thin float and low market capitalization are contributing to its rapid price increases, with some analysts comparing it to a smaller-scale version of a similar biotech name that has seen significant gains.
The company's recent patent application for ART27.13, a potential treatment for obesity, has been well-received, with some analysts predicting that it could lead to a significant increase in the company's value, potentially reaching $20.00 or more.

Bearish· Sep 23

*ARTL has dropped significantly after hours, and some users are advising to sell at a loss.*
The short sellers are being let out of their positions, causing the price to drop to $8.
The halt has caused orders to stack, and some users are anticipating a further decline in price to $13.

Generated by AI

Topics

Of the messages about ARTL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	25.69%	29.31%	38.68%
Technical Analysis	—	19.27%	18.1%	28.48%
Analysts	—	20.18%	19.4%	15.6%
Macro	—	20.18%	18.97%	15.06%
Earnings	—	14.68%	13.79%	1.94%
Controversies	—	0%	0.43%	0.24%

Announcements· Jul 8

Artelo Biosciences, Inc. (ARTL) is experiencing a decline today, trading at $1.005 with a drop of -7.37%.
The company is facing a tough day, priced at $1.005 and down by -7.37%, reflecting a significant decrease in its stock value.
Artelo Biosciences, Inc. (ARTL) is in a pullback phase today, priced at $1.005 with a decrease of -7.37%, indicating a reduction in its stock value.

Technical Analysis· Mar 27

Resistance levels for $ARTL are $10.00 to $12.00, and breaking through will lead to a move to $15.00 to $20.00 or higher.
A breakout above $18.00 with volume could trigger a continuation of the upward trend, with $20.00 as the next psychological level.
A quadruple top pattern at the $15.00 level may be a sign that $ARTL is due for a breakout, but it needs to hold above this level to confirm the pattern.

Generated by AI

Community

Of the messages about ARTL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	27.38%	29.13%	24.3%
Newcomers	50%	72.62%	70.87%	75.7%

Regulars· Sep 23

The stock price of $ARTL has increased by over 154% so far, with a current price of $10.98, and has been halted several times due to high volume.
The company has filed a new provisional patent application covering ART27.13 for obesity, alone and in combination with GLP-1 receptor agonists, following unexpected nonclinical findings.
The stock is expected to continue its upward trend, with some analysts predicting a price of $40 or more, although a reversal is also possible.

Newcomers· Sep 24

The company's stock price increased significantly, breaking through a resistance area and showing strong momentum, with a surge in volume to 25M.
The low float of the stock is mentioned as a potential reason for its price movement, with some users noting that the stock could "blow the roof off" if not halted.
The stock's performance is compared to other assets, with some users noting that it has the potential to be a "banger" or a "next leg up," and that it has already shown a significant increase in value.

Generated by AI

Artelo Biosciences, Inc. (NASDAQ: ARTL) shares are surging Wednesday afternoon after the clinical-stage biopharmaceutical company announced the filing of a new provisional patent application covering its drug candidate ART27.13 for the treatment of obesity.

6d agoBenzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session - Artelo Biosciences (NASDAQ:ARTL), Vistagen

Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million. Vistagen Therapeutics (NASDAQ:VTGN) shares

6d agoBenzinga

Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks Application expands Artelo’s intellectual property position for ART27.13 into obesity, where J.P. Morgan has projected the global GLP-1 market could reach $200 billion by 2030 New findings show the combination further improved oral glucose tolerance and increased bone mineral density, an effect not observed in

7d agoYahoo Finance

Artelo Cannabinoid Drug Doubles Weight Loss When Paired with Popular Obesity Drug

13d agobenzinga.com

Artelo’s ART27.13 matches semaglutide weight loss in mice study

14d agoInvesting.com

Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity

Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic® and Wegovy® Combining ART27.13 with semaglutide produced approximately 40% weight loss – double that of semaglutide alone Results indicate that ART27.13 may possess the profile of a “metabolic regulator” capable of differentially modifying body weight and other parameters depending on the metabolic phenotype being treated SOLANA B

14d agoYahoo Finance UK

Also Discussed

Investors talking about ARTL also mention

#	Name	Attention
1	EpicQuest Education Group International LimitedEEIQ	0%0
2	METX - Meten Holding Group Ltd.	——
3	ReTo Eco-Solutions Inc. Class A SharesRETO	0.02%+0
4	CLPS Inc.CLPS	0%new
5	Flash Sports & Media, Inc.UGRO	0%new
6	Sky Quarry Inc.SKYQ	0%-0.01
7	Research Solutions Inc.RSSS	0%new
8	SciSparc Ltd.SPRC	0%+0
9	EM - Smart Share Global Limited	——
10	Oxbridge Re Holdings LimitedOXBR	0%0

Artelo Biosciences, Inc.

Healthcare
Biotechnology

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing proprietary therapeutics that modulate lipid-signaling pathways. Artelo Biosciences concentrates on treatments for conditions with significant unmet medical needs, including cancer-related anorexia, pain, inflammation, anxiety, dermatologic disorders, and other serious diseases. Its current pipeline includes product candidates such as ART27.13, ART12.11, and ART26.12, which are being developed across multiple therapeutic areas with an emphasis on endocannabinoid and fatty acid binding protein biology. The company’s work centers on advancing novel small-molecule and cannabinoid-based approaches aimed at improving care in oncology, neurology, and related fields. Artelo Biosciences is headquartered in Solana Beach, California, and operates as a research-driven company within the broader pharmaceutical market.

Website

Location

505 Lomas Santa Fe

Solana Beach, CA, 92075

United States

Social

What share of all stock conversation is about ARTL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0.02% +0.02	0.01% +0	0% +0

Sep 24

The stock price of ARTL surged from around $4 to $7.31, breaking through the $5.46 area with significant momentum and volume.
The company's stock has experienced a significant increase, with some investors reporting gains of over 75% in a short period, despite previous volatility and haltings.
The stock's low float and high volatility have contributed to its potential for significant price movements, with some investors anticipating further increases in the stock's price.

Generated by AI

Sentiment

Of the messages about ARTL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% -50	83.08% -7.83	83.58% +1.76	78.83% -1.56
Bearish	50% new	16.92% +7.83	16.42% -1.76	21.17% +1.56

Bullish· Sep 23

The company has already shown significant price appreciation, rising by 168% from $4.70 to $12.63, and is expected to continue its upward trend with a potential daily expansion move to $14.60+.
The asset's thin float and low market capitalization are contributing to its rapid price increases, with some analysts comparing it to a smaller-scale version of a similar biotech name that has seen significant gains.
The company's recent patent application for ART27.13, a potential treatment for obesity, has been well-received, with some analysts predicting that it could lead to a significant increase in the company's value, potentially reaching $20.00 or more.

Bearish· Sep 23

*ARTL has dropped significantly after hours, and some users are advising to sell at a loss.*
The short sellers are being let out of their positions, causing the price to drop to $8.
The halt has caused orders to stack, and some users are anticipating a further decline in price to $13.

Generated by AI

Topics

Of the messages about ARTL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	25.69%	29.31%	38.68%
Technical Analysis	—	19.27%	18.1%	28.48%
Analysts	—	20.18%	19.4%	15.6%
Macro	—	20.18%	18.97%	15.06%
Earnings	—	14.68%	13.79%	1.94%
Controversies	—	0%	0.43%	0.24%

Announcements· Jul 8

Artelo Biosciences, Inc. (ARTL) is experiencing a decline today, trading at $1.005 with a drop of -7.37%.
The company is facing a tough day, priced at $1.005 and down by -7.37%, reflecting a significant decrease in its stock value.
Artelo Biosciences, Inc. (ARTL) is in a pullback phase today, priced at $1.005 with a decrease of -7.37%, indicating a reduction in its stock value.

Technical Analysis· Mar 27

Resistance levels for $ARTL are $10.00 to $12.00, and breaking through will lead to a move to $15.00 to $20.00 or higher.
A breakout above $18.00 with volume could trigger a continuation of the upward trend, with $20.00 as the next psychological level.
A quadruple top pattern at the $15.00 level may be a sign that $ARTL is due for a breakout, but it needs to hold above this level to confirm the pattern.

Generated by AI

Community

Of the messages about ARTL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	27.38%	29.13%	24.3%
Newcomers	50%	72.62%	70.87%	75.7%

Regulars· Sep 23

The stock price of $ARTL has increased by over 154% so far, with a current price of $10.98, and has been halted several times due to high volume.
The company has filed a new provisional patent application covering ART27.13 for obesity, alone and in combination with GLP-1 receptor agonists, following unexpected nonclinical findings.
The stock is expected to continue its upward trend, with some analysts predicting a price of $40 or more, although a reversal is also possible.

Newcomers· Sep 24

The company's stock price increased significantly, breaking through a resistance area and showing strong momentum, with a surge in volume to 25M.
The low float of the stock is mentioned as a potential reason for its price movement, with some users noting that the stock could "blow the roof off" if not halted.
The stock's performance is compared to other assets, with some users noting that it has the potential to be a "banger" or a "next leg up," and that it has already shown a significant increase in value.

Generated by AI

Artelo Biosciences

Social

Sep 24

Bullish· Sep 23

Bearish· Sep 23

Announcements· Jul 8

Technical Analysis· Mar 27

Regulars· Sep 23

Newcomers· Sep 24

Artelo Biosciences (ARTL) Stock Surges Wednesday: What's Happening? - Artelo Biosciences (NASDAQ:ARTL)

12 Health Care Stocks Moving In Wednesday's Intraday Session - Artelo Biosciences (NASDAQ:ARTL), Vistagen

Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

Artelo Cannabinoid Drug Doubles Weight Loss When Paired with Popular Obesity Drug

Artelo’s ART27.13 matches semaglutide weight loss in mice study

Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity

Also Discussed

Artelo Biosciences, Inc.

Company Information

Location

Artelo Biosciences (ARTL) Stock Surges Wednesday: What's Happening? - Artelo Biosciences (NASDAQ:ARTL)

12 Health Care Stocks Moving In Wednesday's Intraday Session - Artelo Biosciences (NASDAQ:ARTL), Vistagen

Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

Artelo Cannabinoid Drug Doubles Weight Loss When Paired with Popular Obesity Drug

Artelo’s ART27.13 matches semaglutide weight loss in mice study

Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity

Also Discussed

Social

Sep 24

Bullish· Sep 23

Bearish· Sep 23

Announcements· Jul 8

Technical Analysis· Mar 27

Regulars· Sep 23

Newcomers· Sep 24